BackCalliditas Therapeutics AB Overview

Calliditas Therapeutics AB Receivables

Calliditas Therapeutics AB's receivables is $220M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$222.59M
↓ 3.10% YoYΔ $-7.12M vs prior year quarter

Peer trimmed avg / median

Loading

Calliditas Therapeutics AB Receivables History

Loading

Calliditas Therapeutics AB vs. peers: Receivables Comparison

Loading

Calliditas Therapeutics AB Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Calliditas Therapeutics AB (CALT) FAQ

As of the most recent data (June 2024), CALT shows a receivables of $220M. That compares with $230M in the prior-year period — down 3.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CALT's receivables is now $220M (was $230M) — a 3.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Calliditas Therapeutics AB is outperforming or lagging.

Tracking CALT's receivables over time shows whether Calliditas Therapeutics AB is scaling, shrinking, or reshaping that part of the business. The current reading is $220M That compares with $230M in the prior-year period — down 3.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Calliditas Therapeutics AB's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $220M) with ownership activity and broader fundamentals.

Calliditas Therapeutics AB's receivables is $220M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.